ROQUEFORT THERAPEUTICS PLC Roquefort Therapeutics plc Share Price
Equities
ROQ
GB00BMDQ2T15
Investment Management & Fund Operators
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.6 GBX | +1.10% |
|
-3.16% | -36.55% |
| 04-26 | EARNINGS AND TRADING: Aura confident in Tiris; Cindrigo enters Germany | AN |
| 04-26 | Earnings Flash (ROQ.L) ROQUEFORT THERAPEUTICS Reports FY23 Loss GBX-1.35 | MT |
| Sales 2021 | 637 799.53 63.7K | Sales 2022 | - | Capitalization | 8.56M 10.74M 856M |
|---|---|---|---|---|---|
| Net income 2021 | - 0 0 | Net income 2022 | -1M -1.26M -100M | EV / Sales 2021 | 10,439 x |
| Net cash position 2021 | 900K 1.13M 89.97M | Net cash position 2022 | 2.32M 2.92M 232M | EV / Sales 2022 | - |
| P/E ratio 2021 |
-3.77
x | P/E ratio 2022 |
-4.24
x | Employees | 9 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 29.02% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.10% | ||
| 1 week | -3.16% | ||
| Current month | -34.29% | ||
| 1 month | -34.29% | ||
| 3 months | -31.85% | ||
| 6 months | -33.09% | ||
| Current year | -36.55% |
1 week
4.41
4.60
1 month
3.857.50
Current year
3.859.50
1 year
3.859.50
3 years
3.8513.63
5 years
3.8513.63
10 years
3.8513.63
| Managers | Title | Age | Since |
|---|---|---|---|
Ajan Reginald
CEO | Chief Executive Officer | 52 | 15/09/22 |
| Chairman | 51 | 16/08/20 | |
Armand Keating
CTO | Chief Tech/Sci/R&D Officer | - | 15/09/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jean Duvall
BRD | Director/Board Member | 63 | 04/04/22 |
Darrin Disley
BRD | Director/Board Member | 57 | 15/09/22 |
| Chairman | 51 | 16/08/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 4.6 | +1.10% | 76 203 |
| 26/04/24 | 4.55 | 0.00% | 421,949 |
| 25/04/24 | 4.55 | -4.21% | 725,100 |
| 24/04/24 | 4.75 | 0.00% | 500,000 |
| 23/04/24 | 4.75 | 0.00% | 1,373 |
Delayed Quote London S.E., April 29, 2024 at 04:35 pm
More quotes
Roquefort Therapeutics PLC is a biotechnology company. The Company is focused on developing pre-clinical medicines focused on treating hard-to-treat cancers. The Companyâs portfolio consists of five fully funded, patent-protected pre-clinical anti-cancer medicines. Its portfolio of medicines includes Midkine antibodies with in vivo efficacy and toxicology studies; Midkine oligonucleotide therapeutics with anti-cancer gene editing action; Midkine mRNA therapeutics targeting solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with in vivo efficacy, and MK cell therapy with direct and NK-mediated anti-cancer action. The Company operates through its subsidiaries Lyramid Pty Ltd (Lyramid) and Oncogeni Ltd. Lyramid is engaged in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression). Oncogeni Ltd has developed two families of cell and RNA oncology medicines.
Calendar
24/10/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -36.55% | 7.32M | |
| -6.29% | 113B | |
| +20.42% | 63.85B | |
| +5.11% | 61.9B | |
| +10.46% | 42.86B | |
| +9.50% | 40.84B | |
| +18.75% | 34.58B | |
| +5.46% | 25.46B | |
| -4.29% | 22.13B | |
| +2.08% | 18.61B |
- Stock Market
- Equities
- ROQ Stock
